- 高级人才招聘
- 中、初级专业技术人才招聘
- 管理、支撑岗位招聘
- 博士后招聘
肿瘤免疫与微生物组
2016-2019 清华大学, 博士后
2019-2024 美国芝加哥大学 博士后、研究助理教授
2024-至今 中国科学院微生物研究所，研究员
2024年 入选国家级相关人才计划
利用临床组织样品、动物模型等，结合多组学测序分析，从“免疫细胞”和“微生物（组）”两个角度，探究微生物或代谢产物如何影响表观调控（RNA修饰、组蛋白修饰等）介导的抗肿瘤免疫反应，阐明微生物或代谢产物与免疫细胞的互作机制。基于研究发现的潜在靶点，开发新型有效的肿瘤免疫治疗“增敏剂”（如益生菌、小分子药物、ADC等）。
At IMCAS
1) Li Y, Gao Y, Wang L*, Si J*. NK cell adaptation in the tumor microenvironment: Insights for NK cell-based immunotherapy. Cytokine and Growth Factor Reviews. 2025. 86:181-198. (co-corresponding author)
2) Si W, Zhao X, et al., Zhang J*, Liu HW*, Wang L*. Lactobacillus rhamnosus GG induces STING-dependent IL-10 in intestinal monocytes and alleviates inflammatory colitis in mice. Journal of Clinical Investigation. 2025;135(3):e174910. (Corresponding author)
3) Wang L*, Weichselbaum RR, He C*. N6-methyladenosine reader YTHDF2 in cell state transition and antitumor immunity (invited review). RNA. 2025;31(3):395-401. (First author & co-corresponding author)
4) Wen C#, Wang L#, et al., He C*, Liang H*, Weichselbaum RR*. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. Journal of Clinical Investigation. 2024;134(23):e181612. (co-first author)
Prior to IMCAS
1) Wang L#, Lynch C#, Pitroda SP#, et al., Weichselbaum RR*. Radiotherapy and immunology. Journal of Experimental Medicine. 2024;221(7):e20232101. (First author)
2) Bugno J#, Wang L#, et al., Fu YX*, Liang H*, Weichselbaum RR*. Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance. Clinical Cancer Research. 2024;CCR-23-3616. (co-first author)
3) Wang L#*, Si W#, Yu X#, et al., He C, Liang H*, Weichselbaum RR*. Epitranscriptional regulation of TGF-β pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. Journal of Clinical Investigation. 2023;133(24):e172919. (First author & co-corresponding author)
4) Wang L*, Katipally RR, Liang H, Yang K, Pitroda S, He C, Weichselbaum RR*. RNA m6A methylation and MDSCs: roles and therapeutic implications for radiotherapy. Med. 2023;4(12):863-874. (First author & co-corresponding author)
5) Wang L#, Dou X#, Chen S#, et al, Luo C*, Liang H*, He C*, Weichselbaum RR*. YTHDF2 inhibition potentiates radiotherapy anti-tumor efficacy. Cancer Cell. 2023;41(7):1294-1308.e8. (First author)
6) Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, Fu Y, Weichselbaum RR*, Zhao X*, Wang L*. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71(3):521-533. (Corresponding author)
7) He L#, Wang L#, Wang Z#, Li T, Chen H, Hu Z, Dimitrov D, Du J*, Liao X*. An Immune Modulating Antibody-Drug Conjugate (IM-ADC) For Cancer Immunotherapy. Journal of Medicinal Chemistry. 2021;11;64(21):15716-15726. (co-first author)
8) Ding X#, Wang L#, et al., Weichselbaum RR*, Yu J*, Hu M*. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia. Journal of Hematology & Oncology. 2021;12;14(1):92. (co-first author)
9) Wang L#, Gao Y#, Zhang G#, Li D#, et al., Hu X*, Wei Z*, Wang W*, Liao X*. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine. 2020;9;12(560):eaax2282. (First author)
